Xcellerex, Inc. Signs Memorandum of Understanding with SK Chemicals Co. Ltd. to Commercialize SK-Developed Vaccines with FlexFactory(R) Platform

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea’s largest industrial groups, for an alliance to develop and commercialize SK-developed vaccines with Xcellerex’s FlexFactory® biomanufacturing platform. The companies expect to define specific terms of the alliance in the coming months.

Back to news